Printer Friendly

NOVO NORDISK UNIT'S PATENT-CASE SETTLEMENT STRENGTHENS LEADERSHIP IN KEY BIOPESTICIDE TECHNOLOGY; R&D UNIT IS ASSIGNED SIX MYCOGEN PATENTS

NOVO NORDISK UNIT'S PATENT-CASE SETTLEMENT STRENGTHENS LEADERSHIP IN KEY
 BIOPESTICIDE TECHNOLOGY; R&D UNIT IS ASSIGNED SIX MYCOGEN PATENTS
 NEW YORK, Aug. 24 /PRNewswire/ -- In a settlement announced today, Entotech Inc., a wholly owned research-and-development unit of Novo Nordisk A/S (NYSE: NVO), settled its patent-infringement and patent- interference claims against Mycogen (NASDAQ: MYCO), protecting its worldwide leadership in biopesticide technologies. In dispute was a technology for protecting corn, potato, and cereal crops, among others, against beetles. The company estimates the worldwide market for protection against these pests ranges from US$500 million to US$700 million. Today's biopesticides claim less that 1 percent of this market. That share is expected to increase significantly on the basis of technological advances and the trend toward integrated pest management systems that put less strain on the environment.
 Novo Nordisk Gains Control
 Following the settlement, Novo Nordisk becomes the sole owner worldwide of all basic patent rights covering Bacillus thuringiensis (B.t.) toxins effective against beetles. In addition to use in biopesticides that replace or supplement chemical insecticides, it is the only technology for developing transgenic plants that are beetle-resistant and the only technology for managing those beetles for which chemical insecticides are not available.
 Specifically, Novo Nordisk was assigned six former Mycogen patents with all related foreign patent rights. In addition, three basic Mycogen patents relating to this technology were disclaimed. Further, Mycogen paid US$4.3 million to Entotech.
 "The Mycogen patents assigned to Entotech, combined with others we hold, cover a basic insecticidal technology, not just products," said Georg Skot, president, Novo Nordisk Plant Protection Division. "Establishing our ownership will enable us to develop licensing programs and strategic alliances more rapidly and on more favorable terms in all markets, for current as well as future products that are based on this technology."
 Novo Nordisk's current product for protecting agricultural crops against beetle infestation, NOVODOR(TM), was introduced in the United States this year. University-supervised field tests prove it is substantially more effective against beetles than any other B.t.-based pesticide now on the market. Worldwide, Novo Nordisk offers the agriculture, forestry and public-health markets 15 biological pesticide products, the industry's broadest and most diverse product range.
 Intellectual Property Rights Are Key to Growth
 "Novo Nordisk's goal has been to gain market leadership on the basis of a proprietary product portfolio," Skot explained. "The integrity of patent protection and intellectual property rights is critical to the growth of the biotechnology industry as well as to the growth of Novo Nordisk."
 Biological pesticides are expected to play an increasingly large role in agriculture, forestry and public health. Unlike most chemical pesticides, they are pest-specific, i.e., they are not toxic to non- target insects, plants, and animals. They also degrade rapidly and naturally without trace in soil or ground water. Novo Nordisk projects the worldwide market for all B.t.-based pesticides to grow at a compound annual growth rate of 20 percent, from US$60 million in 1991 to US$115 million in 1995.
 Novo Nordisk currently offers the world's broadest and most diverse range of biopesticides. Its Plant Protection Division was established in 1987, and in 1990 Novo Nordisk opened Entotech in Davis, Calif. to research and develop microbial insecticides. In less than two years Entotech has made a number of significant discoveries in the biopesticide field.
 Headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S is a global company with a portfolio of businesses, anchored primarily in biotechnology and serving the health care, industrial and agricultural sectors. The world leader in the development and manufacture of insulin and diabetes-care products and the world's largest producer of industrial enzymes, Novo Nordisk employs approximately 10,000 people in 51 companies operating in 40 countries and markets its products in 140 countries. Novo Nordisk A shares are held by the Novo Nordisk Foundation, a private foundation. Novo Nordisk B shares are quoted on the stock exchanges of Copenhagen, London, Zurich, Basel and Geneva. Its ADSs are listed on the New York Stock Exchange under the symbol NVO.
 -0- 8/24/92
 /CONTACT: Margaret Jo Ringsted of Novo Nordisk of North America, 212-867-0123, or (fax) 212-986-6499, or Peter Verrengia of Fleishman- Hillard, 212-265-9150 or (fax) 212-245-0704, for Novo Nordisk of North America/
 /FIRST ADD -- FACT SHEET -- TO FOLLOW/
 (NVO MYCO) CO: Novo Nordisk A/S; Mycogen Inc. ST: New York IN: MTC SU:


TS -- NY009 -- 2472 08/24/92 09:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1992
Words:739
Previous Article:NUTMEG REPORTS NINTH CONSECUTIVE QUARTER OF RECORD SALES AND EARNINGS
Next Article:/FIRST ADD TO NOVO NORDISK'S INVOLVEMENT IN PLANT PROTECTION ABOUT THE AGRICHEMICAL MARKET
Topics:


Related Articles
ENTOTECH AND MYCOGEN SETTLE PATENT SUIT
SECOND ADDITION TO NOVO NORDISK PLANT PROTECTION DIVISION
/SECOND ADD -- NY009 -- BACKGROUNDER/
MYCOGEN ANNOUNCES THIRD QUARTER RESULTS
MYCOGEN'S M-PERIL(TM) BIOINSECTICIDE APPROVED BY EPA FOR COMMERCIAL USE AGAINST CORN BORER
MYCOGEN RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING Bt GENE TECHNOLOGY FOR INSECT-RESISTANT PLANTS
Mycogen Receives U.S. Patents Covering Insect-Resistant Seed Products, Sues Monsanto, Dekalb, Delta & Pine Land for Infringement
Monsanto's insect-protected plants position underscored with Dow AgroScience abandonment of California patent lawsuit.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters